Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
Ellen T McCarthy, Mukut Sharma, Virginia J Savin
https://pubmed.ncbi.nlm.nih.gov/20966123Actively Recruiting
Age: 18Years +
All Genders
ID06334692
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Led by Mario Negri Institute for Pharmacological Research · Updated on 2025-09-04
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying idiopathic nephrotic syndrome (INS), which includes minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS), and comparing it to primary membranous nephropathy (MN). The goal is to evaluate the levels of circulating anti-nephrin autoantibodies, which may play a role in INS and post-transplant FSGS relapse. INS is a serious kidney condition with unclear causes and limited treatment options, especially when it recurs after transplantation. The study involves testing stored blood samples from patients with biopsy-confirmed idiopathic MCD or FSGS and those with membranous nephropathy. These samples will be analyzed using specialized ELISA tests to measure anti-nephrin autoantibody levels. The tests use recombinant nephrin protein and antibodies to detect these autoantibodies in the blood, comparing patients with INS to those with MN. Participants have previously provided consent for their samples to be stored in a certified biobank. Researchers will analyze these samples retrospectively over about one year to measure antibody levels. The study focuses on laboratory analysis without direct patient involvement, aiming to better understand the potential role of anti-nephrin autoantibodies in nephrotic syndrome and its recurrence after kidney transplant.
CONDITIONS
Brief Title
Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adults over 18 years of age
- Patients with biopsy-confirmed idiopathic minimal change disease or focal segmental glomerulosclerosis
- Patients with biopsy-confirmed idiopathic membranous nephropathy
- Patients who have consented to store their samples in the certified CRB biobank
You will not qualify if you...
- Possible secondary causes of nephrotic syndrome or membranous nephropathy at the time of blood collection
- Active viral or bacterial infections at the time of blood collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 1 year to perform analysis
Participants provide serum samples which will be tested for levels of anti-nephrin autoantibodies using ELISA techniques.
1 visit for blood sample collection
Long-term Monitoring
Duration - Up to 1 year
Participants' serum samples are observed retrospectively to assess anti-nephrin autoantibody levels in patients with nephrotic syndrome compared to controls.
No additional visits required
Trial Site Locations
Total: 1 location
1
Clinical Research Center for Rare Disease Aldo e Cele Daccò
Ranica, BG, Italy, 24020
Actively Recruiting
Loading map...
Research Team
F
Federica Casiraghi, PhD
N
Norberto Perico, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Focal segmental glomerulosclerosis.
Vivette D D'Agati, Frederick J Kaskel, Ronald J Falk
https://pubmed.ncbi.nlm.nih.gov/22187987Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.
Lorenzo Gallon, Joseph Leventhal, Anton Skaro...
https://pubmed.ncbi.nlm.nih.gov/22533598Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
Piero Ruggenenti, Barbara Ruggiero, Paolo Cravedi...
https://pubmed.ncbi.nlm.nih.gov/24480824Minimal change disease and idiopathic FSGS: manifestations of the same disease.
Rutger J Maas, Jeroen K Deegens, Bart Smeets...
https://pubmed.ncbi.nlm.nih.gov/27748392Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.
Andrew J B Watts, Keith H Keller, Gabriel Lerner...
https://pubmed.ncbi.nlm.nih.gov/34732507Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
Federica Casiraghi, Marta Todeschini, Manuel Alfredo Podestà...
https://pubmed.ncbi.nlm.nih.gov/37175393Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis.
Giuseppe Salfi, Federica Casiraghi, Giuseppe Remuzzi
https://pubmed.ncbi.nlm.nih.gov/37795085A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence.
Yoko Shirai, Kenichiro Miura, Kiyonobu Ishizuka...
https://pubmed.ncbi.nlm.nih.gov/38110152Anti-nephrin antibodies are not enriched in patients with primary and post-transplant recurrent podocytopathies.
Francesco Pecoraro, Luca Perico, Federica Casiraghi...
https://pubmed.ncbi.nlm.nih.gov/42048157